Technical Analysis for INDP - Indaptus Therapeutics, Inc.

Grade Last Price % Change Price Change
D 8.82 -6.86% -0.65
INDP closed down 6.86 percent on Friday, September 24, 2021, on 18 percent of normal volume. Note that the stock is in oversold territory based on its Slow Stochastic indicator (14, 3, 3) -- sideways movement or a bounce should not be unexpected.

Trend Table & Recent EOD Trading Signals

ADX Long Term Intermediate Term Short Term
Strong N/A N/A Down
Historical INDP trend table...

Date Alert Name Type % Chg
Fell Below 20 DMA Bearish 0.00%
Stochastic Buy Signal Bullish 0.00%
Narrow Range Bar Range Contraction 0.00%
Wide Bands Range Expansion 0.00%
Oversold Stochastic Weakness 0.00%
Crossed Above 20 DMA Bullish -6.86%
Calm After Storm Range Contraction -6.86%
Wide Bands Range Expansion -6.86%
Oversold Stochastic Weakness -6.86%
20 DMA Resistance Bearish 4.75%
Older End-of-Day Signals for INDP ...

   Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App

Alert Time
Rose Above Previous Day's High about 18 hours ago
Up 1% about 18 hours ago
20 DMA Resistance about 18 hours ago
10 DMA Resistance about 18 hours ago
Fell Below 20 DMA about 18 hours ago
View Earlier Intraday Alerts

Get a Trading Assistant

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.


Indaptus Therapeutics, Inc. Description

Indaptus Therapeutics has evolved from more than a century of immunotherapy advances. The Company's approach is based on the hypothesis that efficient activation of both innate and adaptive immune cells and associated anti-tumor and anti-viral immune responses will require a multi-targeted package of immune system activating signals that can be administered safely intravenously. Indaptus' patented technology is composed of single strains of attenuated and killed, non-pathogenic, Gram-negative bacteria, with reduced i.v. toxicity, but largely uncompromised ability to prime or activate many of the cellular components of innate and adaptive immunity. This approach has led to broad anti-tumor and anti-viral activity, including safe, durable anti-tumor response synergy with each of five different classes of existing agents, including checkpoint therapy, targeted antibody therapy and low-dose chemotherapy in pre-clinical models. Tumor eradication by Indaptus technology has demonstrated activation of both innate and adaptive immunological memory and, importantly, does not require provision of or targeting a tumor antigen in pre-clinical models. Indaptus has carried out successful GMP manufacturing of its lead clinical candidate, Decoy20, and is currently completing other IND-enabling studies.


Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Clinical Medicine Immune System Immunotherapy Cancer Immunotherapy Tumor Chemotherapy Virotherapy Cancer Vaccine Immunity Lymphocytes Antibody Therapy

Is INDP a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength


Indicator Value
52 Week High 28.8299
52 Week Low 6.9816
Average Volume 6,648,342
200-Day Moving Average 0.00
50-Day Moving Average 0.00
20-Day Moving Average 9.11
10-Day Moving Average 9.05
Average True Range 2.06
ADX 38.77
+DI 47.65
-DI 14.94
Chandelier Exit (Long, 3 ATRs) 22.65
Chandelier Exit (Short, 3 ATRs) 13.16
Upper Bollinger Bands 11.55
Lower Bollinger Band 6.67
Percent B (%b) 0.44
BandWidth 53.56
MACD Line -0.03
MACD Signal Line -0.02
MACD Histogram -0.0107
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 10.27
Resistance 3 (R3) 10.39 10.02 10.03
Resistance 2 (R2) 10.02 9.65 9.96 9.95
Resistance 1 (R1) 9.42 9.43 9.24 9.30 9.87
Pivot Point 9.06 9.06 8.96 9.00 9.06
Support 1 (S1) 8.45 8.69 8.27 8.34 7.77
Support 2 (S2) 8.09 8.46 8.03 7.69
Support 3 (S3) 7.49 8.09 7.61
Support 4 (S4) 7.37